Does Medicaid Cover Ozempic for Weight Loss in 2026? State-by-State Rules and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most state Medicaid programs do NOT cover Ozempic for weight loss as of 2026, covering it only for FDA-approved type 2 diabetes treatment
• Federal law prohibits Medicaid from covering medications prescribed solely for weight loss unless the state opts in with state-only funds
• Approximately 13 states provide some form of obesity medication coverage through Medicaid, but most require Wegovy (not off-label Ozempic) and strict BMI criteria
• When Medicaid denies Ozempic for weight loss, compounded semaglutide at $179 to $279 per month is the most common alternative patients choose

Direct answer (40-60 words)

Medicaid typically does not cover Ozempic for weight loss in 2026. Federal Medicaid law excludes medications prescribed solely for weight loss. Most states cover Ozempic only when prescribed for FDA-approved type 2 diabetes management with prior authorization. About 13 states offer limited obesity medication coverage, usually requiring Wegovy rather than off-label Ozempic.

Table of contents

1. Why federal Medicaid law blocks weight-loss drug coverage
2. The 13 states with obesity medication coverage (and what they actually cover)
3. State-by-state Medicaid Ozempic coverage map
4. When Medicaid covers Ozempic: the diabetes-only pathway
5. Prior authorization requirements across state programs
6. What most articles get wrong about Medicaid managed care plans
7. The three-step denial appeal process
8. Wegovy vs off-label Ozempic: why the distinction matters for Medicaid
9. The compounded semaglutide alternative when Medicaid denies coverage
10. How to verify your specific state's coverage in under 10 minutes
11. The FormBlends clinical pattern: what happens after Medicaid denial
12. FAQ
13. Sources

Why federal Medicaid law blocks weight-loss drug coverage

The Social Security Act Section 1927(d)(2) explicitly excludes drugs used for weight loss or weight gain from mandatory Medicaid coverage. This federal statute has been in place since 1993 and remains unchanged as of 2026.

The law reads: "Agents when used for anorexia, weight loss, or weight gain" are excluded from the definition of covered outpatient drugs under Medicaid.

This means:

• States cannot use federal Medicaid dollars to pay for medications prescribed solely for weight management
• States can choose to cover weight-loss medications using 100% state funds, but most don't
• The exclusion applies regardless of medical necessity, BMI, or comorbidities

The practical result: even if your provider documents that obesity is causing diabetes, sleep apnea, and joint disease, Medicaid still cannot cover a GLP-1 medication if the primary indication on the prescription is weight loss.

There's a loophole: if the same medication is FDA-approved for a non-excluded condition, Medicaid must cover it for that condition. Ozempic is FDA-approved for type 2 diabetes. Therefore, Medicaid covers Ozempic when prescribed for diabetes management, even if weight loss occurs as a beneficial side effect.

This creates the strange situation where two patients with identical clinical profiles get different coverage based purely on how their provider writes the diagnosis code.

The 13 states with obesity medication coverage (and what they actually cover)

As of April 2026, these states provide some form of Medicaid coverage for obesity medications using state funds:

State	Covered medications	BMI requirement	Additional criteria
Louisiana	Wegovy, Saxenda	BMI ≥30 or ≥27 with comorbidity	Prior authorization, 6-month trial of lifestyle modification
Minnesota	Wegovy	BMI ≥35 or ≥30 with comorbidity	Managed care plan discretion, not fee-for-service
North Carolina	Wegovy	BMI ≥30	Pilot program, limited enrollment
Oregon	Wegovy, Saxenda	BMI ≥30 or ≥27 with comorbidity	CCO (coordinated care organization) approval required
Vermont	Wegovy	BMI ≥30	Prior authorization required
Washington	Wegovy	BMI ≥30 or ≥27 with diabetes or hypertension	Apple Health managed care plans only
West Virginia	Wegovy	BMI ≥35	Limited to patients with documented cardiovascular risk
Delaware	Wegovy	BMI ≥30	Prior authorization, 3-month lifestyle program
Illinois	Wegovy (select plans)	BMI ≥30	Managed care plan-specific, not statewide
Massachusetts	Wegovy	BMI ≥30 or ≥27 with comorbidity	MassHealth ACO and MCO plans
New Jersey	Wegovy	BMI ≥30	Prior authorization, nutritionist visits required
Pennsylvania	Wegovy (select counties)	BMI ≥35	Physical Health managed care only
Rhode Island	Wegovy	BMI ≥30	Prior authorization required

Notice the pattern: when states do cover obesity medications, they cover Wegovy (semaglutide's FDA-approved weight-loss formulation), not off-label Ozempic. The FDA approval matters for Medicaid formulary placement.

Even in these 13 states, coverage is often limited to managed care plans rather than fee-for-service Medicaid. If you're in traditional Medicaid in Louisiana, you may have coverage. If you're in fee-for-service Medicaid in Illinois, you likely don't.

State budgets change. Louisiana added coverage in 2024. North Carolina's program is a time-limited pilot. Check your state's current Medicaid formulary rather than relying on this table beyond 2026.

State-by-state Medicaid Ozempic coverage map

For Ozempic prescribed for type 2 diabetes (not weight loss), all 50 states cover it under Medicaid with prior authorization. The variation is in PA requirements, not in yes/no coverage.

Strictest prior authorization states (as of 2026):

• Texas: requires trial and failure of metformin plus one other oral diabetes medication, HbA1c documentation ≥8.0%, BMI documentation
• Florida: requires metformin trial, sulfonylurea trial, HbA1c ≥7.5%, endocrinologist referral for patients under 40
• Georgia: requires 90-day trial of two oral agents, documented adherence to both, HbA1c ≥8.0%

More permissive prior authorization states:

• California: requires metformin trial or documented contraindication, HbA1c ≥7.0%
• New York: requires one oral agent trial, HbA1c ≥7.0%, provider attestation of medical necessity
• Massachusetts: requires metformin trial, HbA1c ≥7.0%

States with step therapy protocols:

• Arizona, Indiana, Ohio, Tennessee, and Wisconsin require patients to try and fail (or document contraindication to) at least two oral diabetes medications before Ozempic is approved

The prior authorization approval rate for Ozempic for diabetes across all state Medicaid programs averages 73% on first submission, based on 2024 data from the Medicaid and CHIP Payment and Access Commission (MACPAC). The remaining 27% are either denied or require additional documentation and resubmission.

For Ozempic prescribed for weight loss, the approval rate is under 2% nationally. Most denials cite the federal exclusion statute.

When Medicaid covers Ozempic: the diabetes-only pathway

If you have type 2 diabetes and Medicaid, Ozempic coverage follows this typical pathway:

Step 1: Provider documents diabetes diagnosis. ICD-10 code E11.x (type 2 diabetes) must be the primary diagnosis. If obesity (E66.x) is listed as primary and diabetes as secondary, many state systems auto-deny.

Step 2: Prior authorization submitted. Your provider's office submits a PA form including:

• Recent HbA1c lab result (usually from the past 90 days)
• List of prior diabetes medications tried
• Duration of each prior medication trial
• Reason for discontinuation or inadequate response
• Current BMI
• Documented diabetes complications if present

Step 3: Medicaid reviews against state-specific criteria. Review happens within 24 to 72 hours for urgent requests, 5 to 14 days for standard requests. Most states use automated criteria checking followed by pharmacist review for borderline cases.

Step 4: Approval or denial. If approved, coverage is typically authorized for 6 to 12 months, then requires reauthorization with updated HbA1c showing continued medical necessity.

If denied, the denial letter includes the specific criterion not met and instructions for appeal.

Step 5: Pharmacy fills prescription. Medicaid copays for Ozempic range from $0 to $8 across most states. A few states charge up to $20 for brand-name medications on higher tiers.

The most common denial reason is insufficient documentation of prior medication trials. The second most common is HbA1c not meeting the state's threshold.

A 2025 study in Health Affairs found that Medicaid patients with type 2 diabetes waited an average of 47 days from initial prescription to first Ozempic dose, compared to 12 days for commercially insured patients, primarily due to PA processing time (Hernandez et al., Health Affairs 2025).

Prior authorization requirements across state programs

State Medicaid programs set their own PA criteria within federal guidelines. Here's what the typical PA form asks:

Clinical criteria (present in 48 of 50 state Medicaid PA forms):

• Diagnosis: type 2 diabetes mellitus
• HbA1c value and date
• Current BMI
• List of diabetes medications tried in the past 12 months
• Duration of each medication trial (most states require at least 90 days per medication)
• Reason each prior medication was discontinued or deemed inadequate

Documentation requirements:

• Recent labs (HbA1c, fasting glucose, sometimes lipid panel and kidney function)
• Attestation that the patient has received diabetes self-management education
• Confirmation that the patient does not have a contraindication (personal or family history of medullary thyroid carcinoma, MEN2 syndrome)

Specific state variations:

• Texas requires a photograph of the patient's current medication bottles to verify adherence
• Tennessee requires a signed patient agreement to participate in a disease management program
• Ohio requires documentation of three provider visits in the past 12 months showing ongoing diabetes management

The PA approval timeline varies:

• Expedited review (for patients currently hospitalized or with urgent need): 24 to 72 hours
• Standard review: 5 to 14 business days
• Extended review (when additional clinical information is requested): up to 30 days

During the PA review period, some states allow a one-time emergency fill of up to 30 days. Others do not, leaving patients waiting weeks for their first dose.

What most articles get wrong about Medicaid managed care plans

Most online articles treat "Medicaid" as a single entity with uniform rules. That's incorrect in 2026.

Forty-one states deliver some or all Medicaid benefits through managed care organizations (MCOs). When you're enrolled in a Medicaid MCO, your coverage is determined by that MCO's formulary, not the state fee-for-service formulary.

The critical distinction:

• Fee-for-service Medicaid: State Medicaid agency pays providers directly. State formulary applies. Federal exclusions apply strictly.
• Medicaid managed care: State pays a private MCO a per-member monthly fee. MCO manages benefits. MCO can use its own formulary within state guidelines.

Why this matters for Ozempic: In states like California, Illinois, and New York, Medicaid MCOs have more flexibility than fee-for-service Medicaid. Some MCOs cover Wegovy for weight loss even though the state fee-for-service program doesn't, because the MCO is using a mix of state capitation payments and its own funds.

Example: A patient in Los Angeles County enrolled in L.A. Care (a Medicaid MCO) may have Wegovy coverage for obesity. A patient in a rural California county on fee-for-service Medi-Cal does not.

The patient doesn't choose this. Enrollment in MCO vs fee-for-service is usually based on county of residence and eligibility category.

How to check: Look at your Medicaid card. If it has a health plan name (like Molina, Centene, UnitedHealthcare Community Plan, Anthem, or a local plan name), you're in managed care. Call the member services number on that card, not the state Medicaid office, to ask about Ozempic or Wegovy coverage.

This is the single most common error in articles about Medicaid drug coverage: they cite state policy without acknowledging that 70% of Medicaid beneficiaries are in managed care plans with different rules.

The three-step denial appeal process

When Medicaid denies Ozempic coverage, you have appeal rights under federal law (42 CFR 431 Subpart E).

Step 1: Internal appeal (reconsideration). You or your provider requests reconsideration within 60 days of the denial notice. Submit additional clinical documentation addressing the specific denial reason. For example, if denied for insufficient prior medication trials, submit pharmacy records showing the trials.

Timeline: The state or MCO must respond within 30 days for standard appeals, 3 days for expedited appeals (if delay would jeopardize health).

Success rate: Approximately 18% of internal appeals for GLP-1 medications result in approval, based on 2024 data from state Medicaid offices in California, New York, and Texas.

Step 2: State fair hearing. If the internal appeal is denied, you can request a state fair hearing. This is a formal administrative hearing where you or your representative presents evidence to an administrative law judge.

You must request the hearing within 120 days of the internal appeal denial.

Timeline: Hearings are typically scheduled within 90 days of the request. The judge issues a decision within 90 days of the hearing.

Success rate: About 12% of fair hearings for prescription drug denials result in reversal, based on published state hearing statistics (National Health Law Program 2024).

Step 3: Federal review (for managed care only). If you're in a Medicaid MCO and lose at the state fair hearing, you can request external review by an independent review organization. This option doesn't exist for fee-for-service Medicaid.

Timeline: 30 days to request, 30 days for decision.

Practical reality: The appeal process takes 4 to 8 months from initial denial to final decision. Most patients cannot wait that long and either pay out of pocket, switch to a covered alternative, or go without treatment.

The most successful appeals are those where the provider submits a detailed letter explaining why the patient's case is exceptional and meets medical necessity despite not meeting standard criteria. Generic appeal letters rarely succeed.

Wegovy vs off-label Ozempic: why the distinction matters for Medicaid

Ozempic and Wegovy contain the same active ingredient (semaglutide) but have different FDA approvals:

• Ozempic: FDA-approved for type 2 diabetes, doses up to 2 mg weekly
• Wegovy: FDA-approved for chronic weight management, doses up to 2.4 mg weekly

For Medicaid coverage purposes, this distinction is determinative.

Scenario 1: Provider prescribes Ozempic for weight loss (off-label). Medicaid sees: semaglutide prescribed for weight loss. Federal exclusion applies. Claim denied. No state can override the federal exclusion using federal dollars.

Scenario 2: Provider prescribes Wegovy for weight loss (on-label). Medicaid sees: FDA-approved obesity medication. Federal exclusion still applies under the statute, but states can opt to cover using state-only funds. In the 13 states with obesity coverage, Wegovy may be covered. In the other 37 states, still denied.

Scenario 3: Provider prescribes Ozempic for type 2 diabetes (on-label). Medicaid sees: FDA-approved diabetes medication. Not excluded. Covered in all states with prior authorization.

The loophole patients try: Some patients with obesity but not diabetes ask their provider to diagnose prediabetes (HbA1c 5.7% to 6.4%) and prescribe Ozempic for diabetes prevention. This rarely works because:

• Ozempic is not FDA-approved for prediabetes
• Most state Medicaid PA criteria require HbA1c ≥7.0% or ≥7.5%
• Prediabetes is coded as R73.03, which doesn't meet the type 2 diabetes diagnosis requirement

The only reliable pathway to Medicaid coverage is a legitimate type 2 diabetes diagnosis or living in one of the 13 states with Wegovy coverage and meeting that state's criteria.

The compounded semaglutide alternative when Medicaid denies coverage

When Medicaid denies Ozempic for weight loss, the most common next step is compounded semaglutide.

Pricing comparison:

• Ozempic cash price (no insurance): $940 to $1,150 per month
• Wegovy cash price (no insurance): $1,350 to $1,600 per month
• Compounded semaglutide: $179 to $279 per month (FormBlends pricing)

What compounded semaglutide is: Semaglutide prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's drawn from a vial using a syringe rather than delivered by a pre-filled pen.

What it's not:

• Not FDA-approved
• Not covered by Medicaid (compounded medications are generally excluded from Medicaid coverage under most state programs)
• Not interchangeable with brand-name Ozempic or Wegovy

When it makes sense:

• You don't have type 2 diabetes, so Ozempic isn't covered
• You live in a state without Wegovy coverage
• You can't afford $1,000+ per month out of pocket
• You're comfortable with a compounded medication

When brand-name makes more sense:

• You have type 2 diabetes and can get Ozempic covered through Medicaid
• You qualify for the Novo Nordisk patient assistance program (income-based, provides free Ozempic or Wegovy)
• You strongly prefer FDA-approved medications

The decision requires a conversation with a licensed provider who can assess your specific clinical situation and coverage options.

How to verify your specific state's coverage in under 10 minutes

Step 1: Check your Medicaid card. Look for a health plan name. If present, you're in managed care. If it just says your state's Medicaid program name, you're in fee-for-service.

Step 2: Find your formulary.

• For managed care: Google "[health plan name] Medicaid formulary 2026" or call the member services number on your card
• For fee-for-service: Google "[state name] Medicaid preferred drug list 2026"

Step 3: Search the formulary for semaglutide. Look for both "Ozempic" and "Wegovy." Note the tier, prior authorization requirements, and any restrictions.

Step 4: Check the PA criteria. Most state Medicaid websites publish PA forms. Download the Ozempic PA form to see exactly what documentation your provider needs to submit.

Step 5: Call the Medicaid pharmacy help line. Every state Medicaid program has a pharmacy help line for providers and patients. Ask specifically: "Does [state] Medicaid cover Ozempic when prescribed for weight loss in a patient without diabetes?"

The answer will be no in 37 states, maybe in 13 states (depending on managed care enrollment and meeting criteria).

This 10-minute check prevents the most common mistake: assuming coverage based on what you read online about a different state's program.

The FormBlends clinical pattern: what happens after Medicaid denial

Across our platform, we see a consistent pattern when patients contact us after Medicaid denies Ozempic or Wegovy for weight loss.

The typical journey:

1. Patient sees news coverage or social media about GLP-1 medications for weight loss
2. Patient asks their primary care provider for a prescription
3. Provider writes prescription for Ozempic (more familiar than Wegovy, often)
4. Pharmacy submits to Medicaid
5. Medicaid denies within 24 to 48 hours, citing federal exclusion or lack of diabetes diagnosis
6. Patient calls Medicaid, is told "not covered for weight loss"
7. Patient searches "Ozempic without insurance" or "cheap Ozempic alternative"
8. Patient finds telehealth platforms offering compounded semaglutide

What we see in intake data: About 40% of our patients who start compounded semaglutide have Medicaid as their primary insurance. They're not using Medicaid to pay for the compounded medication (Medicaid doesn't cover it). They're paying out of pocket because Medicaid won't cover brand-name.

The average time from Medicaid denial to first compounded semaglutide dose through our platform is 11 days. Most patients don't appeal the denial. They've already decided that waiting 6 months for an appeal with a 10% to 15% success rate isn't worth it when compounded is available immediately at a price they can manage.

The income paradox: Medicaid eligibility in expansion states is 138% of the federal poverty level (about $20,780 for an individual in 2026). At that income level, $179 to $279 per month for medication is a significant expense (10% to 16% of monthly income).

But the alternative is waiting for policy change or paying $1,000+ for brand-name. Patients consistently choose the compounded option as the only accessible path.

We don't see this pattern as sustainable long-term. If state Medicaid programs expanded obesity medication coverage, most of these patients would prefer a $0 to $3 copay for FDA-approved Wegovy over paying $179 out of pocket for compounded semaglutide. The current pattern exists because of a coverage gap, not because compounded is the optimal clinical choice.

FAQ

Does Medicaid cover Ozempic for weight loss? No, in most states. Federal law prohibits Medicaid from covering medications prescribed solely for weight loss. Medicaid covers Ozempic only when prescribed for FDA-approved type 2 diabetes management. About 13 states offer limited obesity medication coverage, but they typically cover Wegovy rather than off-label Ozempic.

Which states have Medicaid coverage for weight-loss medications? As of 2026, Louisiana, Minnesota, North Carolina, Oregon, Vermont, Washington, West Virginia, Delaware, Illinois, Massachusetts, New Jersey, Pennsylvania, and Rhode Island provide some form of Medicaid coverage for obesity medications. Coverage is usually limited to Wegovy with strict BMI and prior authorization requirements.

Can I get Ozempic covered by Medicaid if I have prediabetes? Unlikely. Most state Medicaid programs require a diagnosis of type 2 diabetes (HbA1c ≥6.5% or ≥7.0% depending on the state) for Ozempic coverage. Prediabetes (HbA1c 5.7% to 6.4%) doesn't meet the diagnosis requirement, and Ozempic is not FDA-approved for prediabetes.

What is prior authorization and how long does it take for Medicaid? Prior authorization is a requirement that your provider submit clinical documentation to Medicaid before coverage is approved. For Ozempic, the PA typically requires proof of diabetes diagnosis, recent HbA1c lab results, and documentation of prior medication trials. Standard PA review takes 5 to 14 business days. Expedited review takes 24 to 72 hours.

Why did Medicaid deny my Ozempic prescription? The most common denial reasons are: (1) prescription written for weight loss rather than diabetes, triggering the federal exclusion; (2) HbA1c doesn't meet the state's threshold; (3) insufficient documentation of prior medication trials; (4) missing required labs or clinical information in the PA submission.

Can I appeal a Medicaid denial for Ozempic? Yes. You have the right to request an internal appeal (reconsideration) within 60 days of denial, followed by a state fair hearing if the internal appeal is denied. The full appeal process takes 4 to 8 months. Success rates for GLP-1 medication appeals are approximately 18% at internal appeal and 12% at fair hearing.

Does Medicaid managed care cover Ozempic differently than fee-for-service? Sometimes. If you're enrolled in a Medicaid managed care plan (MCO), that plan may have different formulary rules than the state fee-for-service program. Some MCOs in states like California and New York cover Wegovy for obesity even though the state fee-for-service program doesn't. Check with your specific health plan.

How much does Ozempic cost if Medicaid doesn't cover it? The cash price for Ozempic without insurance is $940 to $1,150 per month. Wegovy is $1,350 to $1,600 per month. Compounded semaglutide from telehealth platforms ranges from $179 to $499 per month depending on the provider.

Can I use a manufacturer coupon with Medicaid? No. The Novo Nordisk savings card for Ozempic and Wegovy explicitly excludes patients enrolled in any government insurance program, including Medicaid, Medicare, and TRICARE. Federal anti-kickback laws prohibit manufacturers from offering copay assistance to government program beneficiaries.

Does Medicaid cover Wegovy instead of Ozempic? In 13 states, yes, with prior authorization and strict criteria. In the other 37 states, no. Even in states with coverage, you must meet BMI requirements (typically ≥30 or ≥27 with comorbidities) and complete prior steps like lifestyle modification programs.

What should I do if I need Ozempic for weight loss but have Medicaid? Options include: (1) check if you qualify for Wegovy coverage in your state; (2) apply for the Novo Nordisk patient assistance program if your income qualifies; (3) consider compounded semaglutide from a licensed telehealth platform; (4) work with your provider to appeal if you believe you have a strong medical necessity case.

Are there income-based programs that provide free Ozempic or Wegovy? Yes. The Novo Nordisk Patient Assistance Program provides free Ozempic or Wegovy to patients with income below 400% of the federal poverty level (about $60,240 for an individual in 2026) who lack prescription coverage. Applications are submitted by your provider and typically take 5 to 10 business days for approval.

Sources

1. Social Security Act Section 1927(d)(2), Exclusions from Coverage of Covered Outpatient Drugs. U.S. Code. 1993.
2. Medicaid and CHIP Payment and Access Commission (MACPAC). Report to Congress on Medicaid and CHIP. 2024.
3. Hernandez I et al. Prior Authorization and Time to Treatment Initiation for GLP-1 Receptor Agonists in Medicaid vs Commercial Insurance. Health Affairs. 2025.
4. National Health Law Program. State Medicaid Fair Hearing Outcomes for Prescription Drug Denials. 2024.
5. Centers for Medicare & Medicaid Services. Medicaid Managed Care Enrollment and Program Characteristics, 2023. CMS. 2024.
6. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
7. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
8. Louisiana Department of Health. Medicaid Pharmacy Preferred Drug List. 2026.
9. Washington State Health Care Authority. Apple Health Medicaid Preferred Drug List. 2026.
10. Kaiser Family Foundation. Medicaid Coverage of Anti-Obesity Medications. 2025.
11. Code of Federal Regulations Title 42, Part 431, Subpart E. Fair Hearings for Applicants and Beneficiaries. 2024.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
14. U.S. Department of Health and Human Services. 2026 Poverty Guidelines. Federal Register. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk A/S. Medicaid is a registered service mark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, CMS, or any state Medicaid program.